Management of Tuberculosis to provide doctors and patients in Singapore with evidence-based treatment for tuberculosis. This article reproduces the introduction and executive summary (with recommendations from the guidelines) from the MOH clinical practice guidelines on Prevention, Diagnosis and Management of Tuberculosis, for the information of SMJ readers. The chapters and page numbers mentioned in the reproduced extract refer to the full text of the guidelines, which are available from the Ministry of Health website: http://www.moh.gov.sg/content/moh_web/healthprofessionalsportal/ doctors/guidelines/cpg_medical.html. The recommendations should be used with reference to the full text of the guidelines. Following this article are multiple choice questions based on the full text of the guidelines.
INTRODUCTION
Tuberculosis continues to be a disease of public health importance in Singapore and worldwide. According to the World Health Organisation's Global Tuberculosis Report 2014, an estimated 9 million people developed tuberculosis and 1.5 million died from the disease. Issues like delayed detection and missed opportunities for treatment, and the emergence of drug-resistance are also of increasing concern.
Aim
The target audience is all healthcare practitioners in Singapore. These guidelines aim to:
• Increase knowledge and awareness of tuberculosis so as to facilitate the early detection of active tuberculosis.
• Serve as an evidence-based resource to provide guidance on the use of tuberculosis diagnostic tools and treatment regimens.
• Inform regarding the public health measures necessary for the control of tuberculosis control in Singapore.
Scope
These guidelines will cover tuberculosis referral and diagnosis, treatment of active and latent tuberculosis, and public health actions required on the part of treating physicians. The standards of diagnosis and treatment, which are outlined in the International Standards for Tuberculosis Care, will also be referenced in the clinical practice guidelines (CPG).
Target group
The content of the guidelines will be useful for all healthcare professionals and public health service providers who encounter patients with tuberculosis. The CPG will be applicable to the diagnosis and management of both adult and paediatric patients. The doctor evaluating the patient is ultimately responsible for clinical decisions made after reviewing the individual patient's history, clinical presentation and treatment options available.
Development of guidelines
These guidelines have been produced by a committee of respiratory physicians, infectious disease consultants, and representatives from polyclinics and the College of Family Physicians Singapore, as well as representatives from Ministry of Health (MOH) and Tuberculosis Control Unit appointed by the MOH. They were developed by the adaptation of existing guidelines, by the review of relevant literature and by expert clinical consensus with consideration of local practice. The following principles underlie the development of these guidelines:
• Treatment recommendations are supported by scientific evidence and expert clinical consensus.
• Treatment should maximise therapeutic and public health benefits and minimise side effects.
Review of guidelines
Evidence-based CPGs are only as current as the evidence that supports them. Users must keep in mind that new evidence could supersede recommendations in these guidelines. The workgroup advises that these guidelines be scheduled for review five years after publication, or when new evidence appears that requires substantive changes to the recommendations. 
EXECUTIVE SUMMARY OF RECOMMENDATIONS

Initiation of treatment
18
Patients with chest radiographic findings that suggest active disease may be commenced on tuberculosis treatment even before bacteriological results are available.
GPP 50
19 Tuberculosis treatment should be seriously considered in symptomatic patients despite the X-ray appearances of inactivity.
GPP 50 20
Before starting tuberculosis treatment, baseline liver enzymes should be performed in those over 15 years old. Adult patients to be commenced on ethambutol must have their visual acuity and colour vision checked at baseline.
GPP 50
Treatment regimens for pulmonary tuberculosis 21
6-month standard regimen
The 6-month standard treatment regimen comprising a 2-month intensive phase of ethambutol, isoniazid, rifampicin and pyrazinamide followed by a 4-month continuation phase of rifampicin and isoniazid is the regimen of choice for pulmonary tuberculosis.
Grade A, Level 1++ 51 22
9-month regimen
For patients who are unlikely to tolerate pyrazinamide (e.g. the elderly, those with liver disease), a 9-month regimen comprising ethambutol, rifampicin and isoniazid for 2 months followed by rifampicin and isoniazid for 7 months may be used.
Grade A, Level 1+ 51
Treatment of extrapulmonary tuberculosis
Note: Extrapulmonary tuberculosis is generally treated with the same regimen (6-or 9-month) as pulmonary tuberculosis. Please refer to additional recommendations below:
Tuberculous meningitis 23 Tuberculous meningitis should be treated with the standard tuberculosis regimen but extended to 12 months. Steroids should be used as an adjunct.
Grade B, Level 2+ 52
Musculoskeletal tuberculosis
24
The preferred treatment duration for musculoskeletal tuberculosis is 9 months with a rifampicin-containing regimen.
Grade A, Level 1+ 53
Miliary tuberculosis
25
Miliary tuberculosis (in the absence of central nervous system or musculoskeletal involvement) may be treated with the standard 6-month treatment regimen.
Grade D, Level 4 53
Pleural tuberculosis 
HIV co-infection
34
The standard six-month treatment regimen is recommended for HIV co-infected patients with pulmonary tuberculosis. As with non-HIV-infected patients, the treatment should be extended to 9 months in patients with tuberculous osteomyelitis and to 12 months in patients with central nervous system tuberculosis. 
Management of multidrug-resistant/extensively drug-resistant tuberculosis
43
A multidrug-resistant treatment regimen must contain at least four drugs, preferably more, (including a later-generation fluoroquinolone and a second-line injectable agent) to which the organism is shown to be susceptible and to which the patient has previously not been exposed.
Grade D, Level 3 68 44
Multidrug-resistant tuberculosis (MDR-TB) patients should be treated under strict programme conditions by physicians experienced in MDR-TB management. Directly observed therapy (DOT) should be utilised for the entire treatment duration.
Tuberculosis Contact Investigations and Screening
No. Recommendation Grade, Level of evidence CPG page no. 
63
Children with persistent, unremitting cough for 2 weeks, plus objective weight loss, together with fatigue, should be evaluated for tuberculosis.
Grade C, Level 2+ 85 64 All children being evaluated for latent or active tuberculosis (pulmonary or otherwise) should have a frontal chest radiograph. Where tuberculosis is strongly suspected, a lateral radiograph should be performed even if the frontal view is normal.
Grade C, Level 2+ 86 65 Currently available scoring systems for predicting tuberculosis in children lack sensitivity and/or specificity, and are not recommended to be used for diagnosis.
Grade B, Level 2++ 87
66
In children younger than 5 years old suspected of having tuberculosis infection or disease, the tuberculin skin test (TST) is the preferred mode of initial immunological assessment.
Grade B, Level 2++ 88 67 When interferon-gamma release assay (IGRA) testing is performed in children < 4 years old, the T-SPOT.TB is preferred over the QFT-GIT due to a lower incidence of indeterminate results.
Grade C, Level 2+ 88 68 Because of its excellent specificity, children with a positive interferon-gamma release assays (IGRA) are considered to have tuberculosis infection or disease, and should be offered treatment.
Grade B, Level 2++ 88 69 For children with a clinical suspicion of tuberculosis disease with a negative tuberculin skin test (TST), the interferon-gamma release assay (IGRA) may be performed to increase sensitivity. However, treatment for tuberculosis should be considered when other factors are strongly supportive of tuberculosis (epidemiologic, radiologic, histologic, microbiologic), and neither a negative TST nor IGRA should delay treatment.
